Research aimed to understand how using daily skin care such as a mild cleanser and moisturizer impacts skin health.
A randomized, investigator-blinded study recently published in the Journal of Dermatological Treatment evaluated 52 patients with moderate to severe dry skin to determine how a daily skin care routine of a mild cleanser and moisturizer impacts skin health and quality-of-life (QoL).1 While it is known that moisturizing skin care products can have beneficial effects on dry skin, the role of a daily skin care routine is understudied, according to authors.
Of the 52 patients included in the trial, 39 used mild cleanser and moisturizer twice daily for 2 weeks and the other 13 patients used mild cleanser without moisturizer. The total clinical score (TSC) which included erythema, scale and fissures, Visual Dryness Score (VDS), and subjective itch-related quality-of-life (ItchyQoL) data were collected.
There was significantly more improvement in TCS and VDS in the treatment group vs control after 2 weeks. Also, in the 3 components of IthcyQoL, symptoms, functioning, and emotions, the treatment group demonstrated a greater improvement compared to the control group. More than 80% of the patients in the treatment group also agreed that the regimen led to a decrease in both dryness and itch while improving the skin texture.
Overall, a consistent skin care regimen should be an integral component of management of dry skin, the authors concluded.
This article was originally published by Dermatology Times.
Reference
1. Kim S, Ly BK, Ha JH, et al. A consistent skin care regimen leads to objective and subjective improvements in dry human skin: investigator-blinded randomized clinical trial. Journal of Dermatological Treatment. 2020;0(0):1-6. doi:10.1080/09546634.2020.1751037
Recognize & Refer: Hemangiomas in pediatrics
July 17th 2019Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.
Pz-cel granted FDA Priority Review to treat recessive dystrophic epidermolysis bullosa
November 28th 2023The FDA granted Priority Review to pz-cel following a phase 1/2 and a pivotal phase 3 study in which the treatment for recessive dystrophic epidermolysis bullosa (RDEB) demonstrated wound healing and pain reduction.
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
IDP-126 topical gel approved by FDA to treat acne in patients 12 years and up
October 21st 2023The topical gel is the first and only FDA-approved triple-combination, fixed-dose topical treatment for acne, and is set to be available in the first quarter of 2024, according to Bausch Health Companies Inc.
A 13-year-old girl with well-demarcated rash on back and chest
October 19th 2023A healthy 13-year-old girl presented with a 1-month history of an asymptomatic, well-demarcated rash on her back and upper chest. The eruption consisted of discrete, dark brown papules that coalesced into large, flat-topped plaques with mild superficial scale and accentuation of skin markings. What's the diagnosis?